Highly selective, non-ATP competitive inhibitor of GSK-3β (IC50=2µM). Binds to the active site of GSK-3β. Does not significantly affect the activities of Cdk-1/cyclin B, CK-II, cAMP-dependent protein kinase (PKA), and protein kinase C (PKC) (IC50>100µM).
Product Details
| Alternative Name: | 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione |
| |
| Formula: | C10H10N2SO2 |
| |
| MW: | 222.3 |
| |
| CAS: | 327036-89-5 |
| |
| Purity: | ≥95% (HPLC) |
| |
| Appearance: | White to off-white solid. |
| |
| Solubility: | Soluble in DMSO (10mg/ml). |
| |
| Shipping: | Ambient Temperature |
| |
| Long Term Storage: | +4°C |
| |
| Handling: | Protect from light. Keep under inert gas. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Oncogenic signaling inhibits c-FLIP L expression and its non-apoptotic function during ECM-detachment: M.A. Tsegaye, et al.; Sci. Rep.
11, 18606 (2021),
Abstract;
First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease: A. Martinez, et al.; J. Med. Chem.
45, 1292 (2002),
Abstract;
Full Text
